Home Market Jubilant Life Sciences Ltd.

Jubilant Life Sciences Ltd. Stock Info: As on 2017-11-22 12:19:55

Nse

638.00

-11.95(-1.84%)
Change%
52 Week Range
555.00
26.00
878.00
12.00
Open654.00
Day's Range519.96 - 779.94
Value Traded (in ₹ Cr.) 6.81

Bse

639.00

-9.95(-1.53%)
Change %
52 Week Range
552.40
26.00
879.10
12.00
Open651.00
Day's Range519.16 - 778.74
Value Traded (in ₹ Cr.) 0.88

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 6,970,380.00 4.38%
IndianPromoters 79,080,676.00 49.65%
Mutual Funds/UTI 7,598,928.00 4.77%
FII 30,863,510.00 19.38%
Employee 0.00 0.00%
Public 21,987,068.00 13.80%
Government 0.00 0.00%
Others 8,420,281.00 5.29%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 2.50
Basic EPS (Rs.) 4.96
Cash EPS 10.42
BVPerShare Excl 124.45
Operating Revenue 166.74
PBDITPerShare 25.27
Dividend 3.00
NPPerShare 4.96
Current Ratio 0.89
Quick Ratio 0.49
PriceToBV 3.35
Earnings 0.01
PBDIT Margin 15.15
PBT Margin 3.44
NP Margin 2.97
Return On Assets 1.75
Retention Ratios 39.56
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,717.91
Total Expenses 2,604.57
EBITDA 402.63
PBT 91.41
PAT 79.07
Net Income 79.07
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,289.82
Total Expenses 1,152.62
EBITDA 93.58
PBT 30.19
PAT 20.76
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 15.93
Net worth 1,982.50
Investments 1,706.83
Total Liability 4,503.45
Total debt 1,556.53
Net block 1,446.95
Total Assets 4,503.45
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 15.93
Net worth 1,982.50
Investments 1,706.83
Total Liability 4,503.45
Total debt 1,556.53
Net block 1,446.95
Total Assets 4,503.45
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

536 531.05 0.93
521.1537

Abbott India Ltd.

4988 4990.85 -0.06
4810.055050

Ajanta Pharma Ltd.

1347.4 1344.9 0.19
12141351.95

Albert David Ltd.

305 300.6 1.46
275.1304.45

Alembic Ltd.

39.1 39.45 -0.89
38.540.45

Alembic Pharmaceuticals Ltd.

517 516.25 0.15
507.4532.2

Alkem Laboratories Ltd.

1955 1954.05 0.05
19502018.95
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

57.95 55.8 3.85
44.0562.15

Aarti Drugs Ltd.

534.05 530.75 0.62
513.4537

Aayush Food & Herbs Ltd.

50.4 49.75 1.31
39.1552.7

Abbott India Ltd.

4985 4996.1 -0.22
48455085

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 140.37
Cash from investing activities 521.70
Cash from financing activities -760.51
Net change in cash -98.44

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Motilal Oswal MOSt Focused Multicap 35 Fund 3.47%
Motilal Oswal MOSt Focused Dynamic Equity Fund 2.89%
Motilal Oswal Most Focused Long Term Fund 4.21%
Motilal Oswal MOSt Focused Midcap 30 Fund 2.00%
L&T India Value Fund - Regular Plan 0.42%
LIC MF Mid Cap Fund 1.64%

Advik Capital announces stock split

Advik Capital Ltd. has announced that the Board of Directors of the Company August 11, 2017 approved split of every 1.00 equity share of the company having face value Rs 10.00 each into 9 equity shares of face value Rs 1.00 each, subject to approval of the shareholders. Meanwhile, shares of company were trading at Rs 37.00 apiece, down -3.01 per cent, on the Bombay Stock Exchange.

21-11-2017 20:50

Patspin India posts Q2 net loss of Rs 2.22 cr

The company reported standalone net loss during the quarter stood at Rs 2.22 crore compared to net profit of Rs 1.86 crore in the previous year quarter. Net revenue of the company rose by 0.73 per cent at Rs 128.93 crore in July-September quarter of this fiscal as against Rs 127.99 crore in the corresponding period last year. During July-September quarter, operating expenses increased by 5.39 per cent to Rs 123.09 crore from Rs 116.79 crore in year ago period. Other Income dipped by 29.63 per cent at Rs 0.19 crore versus (Sep'16 Rs 0.27 crore). Operating Profit slipped by 57.86 per cent to Rs 5.84 crore as against Rs 13.86 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 58.17 per cent in September quarter. Interest declined by 7.15 per cent y-o-y to Rs 8.05 crore, while Taxation decreased by 508.47 per cent at Rs -2.41 crore (Sep'16 Rs 0.59 crore).

21-11-2017 18:50

Meyer Apparel posts Q2 net loss of Rs 2.46 cr

The company reported standalone net loss during the quarter stood at Rs 2.46 crore as compared to net loss of Rs 0.39 crore in the previous year quarter. Net revenue of the company declined substantially by 49.64 per cent at Rs 2.78 crore in July-September quarter of this fiscal as against Rs 5.52 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 10.52 per cent to Rs 5.19 crore from Rs 5.80 crore in year ago period. Other Income grew by 0.00 per cent at Rs 0.09 crore versus (Sep'16 Rs 0.00 crore). Operating Profit surged by 760.71 per cent to Rs -2.41 crore as against Rs -0.28 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 1602.55 per cent in September quarter. Interest grew by 100.00 per cent y-o-y to Rs 0.04 crore

21-11-2017 18:40

Garden Silk Mills posts Q2 net loss of Rs 37.64 cr

The company reported standalone net loss during the quarter stood at Rs 37.64 crore as compared to net loss of Rs 20.09 crore in the previous year quarter. Net revenue of the company rose moderately by 13.03 per cent at Rs 708.46 crore in July-September quarter of this fiscal as against Rs 626.79 crore in the corresponding period last year. During July-September quarter, operating expenses increased by 15.16 per cent to Rs 684.14 crore from Rs 594.08 crore in year ago period. Other Income dipped by 25.40 per cent at Rs 0.94 crore versus (Sep'16 Rs 1.26 crore). Operating Profit slipped by 25.67 per cent to Rs 24.32 crore as against Rs 32.72 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 34.29 per cent in September quarter. Interest grew by 22.77 per cent y-o-y to Rs 46.43 crore

21-11-2017 18:40

Shiva Global Agro Q2 net profit zooms 156.52% at Rs 0.59 cr

The company reported standalone net profit of Rs 0.59 crore for the quarter ended September 30, 2017 as compared to Rs 0.23 crore in the same period last year, registering a year-on-yeargrowthof 156.52 per cent. Net revenue of the company declined moderately by 12.50 per cent at Rs 15.96 crore in July-September quarter of this fiscal as against Rs 18.24 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 17.95 per cent to Rs 13.90 crore from Rs 16.94 crore in year ago period. Other Income dipped by 76.92 per cent at Rs 0.03 crore versus (Sep'16 Rs 0.13 crore). Operating Profit surged by 58.46 per cent to Rs 2.06 crore as against Rs 1.30 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 80.79 per cent in September quarter. Interest grew by 17.44 per cent y-o-y to Rs 1.01 crore, while Taxation increased by 150.00 per cent at Rs 0.25 crore (Sep'16 Rs 0.10 crore).

21-11-2017 18:20

Jubilant Life Scienc - Updates

Jubilant Life Sciences Limited has informed the Exchange regarding ''Issuance of Commercial Papers of Rs. 50 crore''.

03-Nov-2017 06:55 PM

Jubilant Life Scienc - Updates

Issuance of Commercial Papers of Rs. 50 crore

03-Nov-2017 06:49 PM

Jubilant Life Scienc - Updates

In continuation of our letter dated October 28, 2017, we enclose copies of the Unaudited Consolidated Financial Results for the quarter ended September 30, 2017 published on October 29, 2017 in Financial Express (English) and HINDUSTAN (Hindi).

30-Oct-2017 12:35 PM

Jubilant Life Scienc - Updates

We enclose a certificate dated October 28, 2017 received from Vistra ITCL (India) Limited, Debenture Trustee, pursuant to Regulation 52 (5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Non-Convertible Debentures of the Company listed on National Stock Exchange of India Limited.

28-Oct-2017 06:48 PM

Jubilant Life Scienc - Financial Results For The Quarter And Half Year Ended September 30, 2017

In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended September 30, 2017 were approved by the Board of Directors of the Company at its meeting held today at 1.45 p.m. and concluded at 4.15 p.m.

Pursuant to the applicable provisions of the Listing Regulations, we enclose the following:

1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended September 30, 2017;
2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; and
3. Copies of the Press Release and Presentation.

We request you to take the same on records.

28-Oct-2017 04:20 PM

Jubilant Life Scienc - Updates

Issuance of Commercial Papers of Rs. 50 crore

03-Nov-2017 06:49 PM

Jubilant Life Scienc - Updates

In continuation of our letter dated October 28, 2017, we enclose copies of the Unaudited Consolidated Financial Results for the quarter ended September 30, 2017 published on October 29, 2017 in Financial Express (English) and HINDUSTAN (Hindi).

30-Oct-2017 12:35 PM

Jubilant Life Scienc - Updates

We enclose a certificate dated October 28, 2017 received from Vistra ITCL (India) Limited, Debenture Trustee, pursuant to Regulation 52 (5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Non-Convertible Debentures of the Company listed on National Stock Exchange of India Limited.

28-Oct-2017 06:48 PM

Corporate Details

About Management

YEAR EVENTS 1978 - The Company was incorporated on 21st June, in Uttar Pradesh. The Company manufacture Vinyl Acetate Monomer (VAM). The Company was promoted by A.B. Bofors (Swedish Multinational), Hindustan Wires Ltd., and Mr. M.L. Bhartia. - The Company entered into a technical collaboration agreement with Noble Chematur Division of A.B. Bofors, Sweden for the supply of know-how and basic engineering for the manufacture of vinyl acetate monomer. 1981 - 1,200 No. of equity shares subscribed for by the signatories to the Memorandum of Association. 34,63,800 No. of equity and 38,500 Pref. shares issued through a prospectus during Mar./Apr. 1982, 19,250 Pref. shares each reserved and allotted to UPSIDC and PICUP. 6,08,370 No. of equity shares reserved and allotted to Indian private promoters and their associates, 6,55,430 No. of equity shares reserved and allotted to AB Brothers of Sweden and 22,00,000 No. of equity shares offered at par for public subscription. Pref. shares redeemable during 28.5.1993/96. 1982 - 6,93,000 Rights Equity shares issued at par in prop. 1:5 (only 5,52,043 shares taken up). The remaining 1,40,357 shares allotted on private placement basis (including 96,800 shares to non-residents). 1983 - Another technical collaboration agreement was signed with Crown Decorative Products Ltd., U.K., and Reed International Company for the manufacture of high pressure emulsions i.e., Polyvinyl Acetate Emulsions. This project was commissioned in 1985-86. - During November, the Company promoted `India Glycols Ltd.' to take up the implementation of a project to manufacture Mono Ethylene Glyco (MEG) at Kashipur, U.P., in technical collaboration with Scientific Design Co. Int., U.S.A. Commercial production commenced on 1st January, 1990. 1984 - A technical collaboration agreement was signed with Technimont Spa of Italy for the manufacture of polyvinyl alcohol with an installed capacity of 2,000 tonnes per annum. The unit was commissioned in July 1991, with an installed capacity of 650 MT per annum. During 1991, the capacity was doubled to 1,400 tonnes per annum. The Company proposed to enhance the capacity of 2,000 MT per annum by installing additional equipment. 1985 - Vam Leasing Ltd., and Vam Investments Ltd., were incorporated as wholly owned subsidiaries of the Company. 1986 - 10,06,180 No. of equity shares issued at par to financial institutions on conversion of loans. 1987 - The Company decided to set up a plant to recover carbon dioxide in collaboration with Hydrogas Denmart a.s. of Denmark and manufacture to dry ice. The plant was commissioned in 1989. A biogas plant was also set up in collaboration with Biotim N.V. of Belgium as a part of energy conservation programme. - The Company also promoted `Insilco Ltd.' jointly with Degussa AG of West Germany for the manufacture of spray dried silica. The project was expected to go on stream by the middle of 1991. - Applications were also submitted to Government for increasing the production capacity of vinyl acetate monomer from 10,000 tonnes to 20,000 tonnes per annum. - In order to part finance the vinyl acetate monomer project, during January, the company privately placed with financial institutions, 15% non-convertible debentures worth Rs 1.00 crores. These debentures are redeemable at a premium of 5% in three equal annual instalments commencing on 27th April, 1993. - The Company privately placed with financial institutions 14% non-convertible debentures worth Rs 1.50 crores. These debentures are redeemable in full at a premium of 5% on 29th December, 1994. 1989 - A synthetic wood adhesive "Vamicol" was launched in January and liquid and dry carbon-di-oxide (dryice) were launched in March. The company installed another new boiler of capacity 25 tonnes steam/hour based on the fluidised bed technology to eliminate air pollution. - The Company privately placed with financial institutions 14% non-convertible debentures worth Rs 10 crores. These debentures are redeemable in full at a premium of 5% on 25th June, 1996. 1990 - The Company commissioned a plant with an installed capacity of 500 tonnes per annum for the manufacture of pyridine and picoline. - The Company undertook to expand the production capacities of vinyl acetate monomer and its intermediaries i.e., acetic anhydride and acetic acid. The expanded capacities were commissioned in October 1990. - The Company privately placed 14% redeemable non-convertible debentures of Rs 100 each aggregating Rs 5.00 crores. These debentures are redeemable at a premium of 5% in three equal annual instalments commencing on 11th September, 1996. - During the year, another 5,00,000-14% redeemable non-convertible debentures of Rs 100 each were privately placed with a provision to redeem at a premium of 5% in three equal instalments commencing on 29th March, 1997. 1992 - Ramganga Fertilizers Ltd. (RFL) was amalgamated with the company effective 1st April, as per BIFR Scheme. As per the scheme of amalgamation 2,56,522 No. of equity shares of Rs 10 each were issued at par to the shareholders of erstwhile RFL in the ratio of one equity share of the company for every 10.35 No. of equity share of Rs 10 each fully paid-up of the erstwhile RFL. 1995 - A technical collaboration agreement was signed with Kemira Coatings Ltd., U.K., to manufacture wood finishes a polymer based product. Another agreement was also signed with M/s. Teutoburg, Germany to manufacture construction chemicals in its plant at Gajraula. - The company proposed to install an additional turbine generator with a capacity of 5.5 MW in view of high and frequently incidence of power failure and fluctuation. The company also proposed to increase the installed capacity of Pyridine & Picolines by 4,000 tonnes per annum to meet the increasing demand for the products. - 2,56,522 No. of equity shares issued to the shareholders of erstwhile RFL on merger of the said company with company. 1996 - The Company proposed to open offices in Singapore to cater to the need of S.E. Asia & China & European markets. With a view to tackling the power failure and fluctuations, the company proposed to instal a turbine generator with a capacity of 5.5 MW. - The company made a capital expenditure of Rs 26.40 crores for taking up projects such as Pyridene & Picolines, wood furnisher, construction chemicals with the intention of saving valuable foreign Exchange. It was also proposed to modernise its sulphuric acid plant. With a view to saving energy the company proposed to instal biogas fired boiler. 1997 - The Company faced a sharp decline in sales realisation of Acetic Acid and VAM, due to a combination of the South East Asian financial debacle and the large capacity build up of Acetic Acid and VAM in South Korean and Singapore. - The company has embarked on a substantial capital expenditure programme to enhance capacities of existing products and also manufacture new products. - Vam Organic Chemicals Ltd has registered a 8.97 per cent increase in net profit for the year ended March 31, 1997 at Rs.23.07 crores as compared to Rs.21.17 crores in the previous year. 1998 - Vam Organics Chemicals has introduced a specialist adhesive Vam Bond 2001. - The dry silica venture, jointly promoted by Vam Organics and Degussa AG of Germany with a 34 per cent stake each has not been doing too well. - The company's performance has been affected due to low international prices, steady increase in prices of major raw materials and sluggish growth in the overall market. - VAM Organic Chemicals Ltd (VOCL) proposes to merge group companies Anichem India Ltd (AIL) and Enpro Speciality Chemicals Ltd (ESCL) with itself. - A planned shut-down of the fertiliser plant was undertaken for 72 days in the quarter for revamping. It also increased its installed capacity from 125 tonnes per day to 175 tonnes per day for sulphuric acid. A captive power plant of 12.45 MW was commissioned in July this year. - VAM Organic Chemicals Ltd is exploring the possibility of entering into areas such as sugar, speciality chemicals and bulk drugs. - The non-convertible debenture programme of Vam Organic Chemicals Ltd has been downgraded by ICRA to LA- LAA-. Vam was the largest player in the alcohol-based organic chemical industry with the largest capacities in the country for most of its products including acetic acid, acetic anhydride, etc. 1999 - VAM Organic Chemicals Ltd (VOCL) has proposed to consolidate and improve its existing position in the chemical industry in the current fiscal. - VOCL has also commissioned the units of Polychem Ltd, manufacturing alcohol-based chemicals in May. - The Company's 22,500 tonnes per annum formaldehyde plant has been commissioned, permitting it to export greater quantities of picolines and pyridines. It has also installed new boilers and increased the capacities of existing plants. 2000 -Enters the Bio / chemo informatics arena by setting up Jubilant Biosys Ltd. 2001 -New corporate identity: Jubilant Organosys Ltd. reflecting changed corporate and business profile 2002 -Acquires the Active Pharmaceutical Ingredients business 2003 -Trading symbol of Jubilant Organosys Limited is changed from 'VAMORGANIC ' to 'JUBILANT' -Jubliant Securites Pvt. Ltd. & Jubliant Capital Pvt. Ltd has acquired 4,38,068 (2.99% of total paid up capital) equity shares. -Mr. H K Khan (Retd. IAS) has been appointed as additional director with effect from November 05, 2003 on the Board. 2004 -Jubilant Organosys Limited has informed that the Board of Directors at their meeting held on January 9, 2004 have approved for voluntary delisting of equity shares of the Company from The Delhi Stock Exchange Association Limited, The Calcutta Stock Exchange Association Limited, Kolkata and the Uttar Pradesh Stock Exchange Association Limited subject to the approval of shareholders by special resolution. -Jubilant Organosys acquires generic pharma Companies in Europe -Jubilant Organosys signs international contracts worth US$ 60 million in CRAMS for the year 2007 2005 -Acquired pharmaceutical company in USA involved in off patent drug development and supply, and owns US FDA approved manufacturing facility for solid dosage forms. -Acquires full service Clinical Research Organization in USA involved in providing clinical research services, data management, biostatistics and contract staffing. -Acquires Target Research Associates, Inc., renamed Clinsys Inc.; a US based Clinical Research Organisation (CRO) -Acquires Trinity Laboratories, Inc. and its wholly owned subsidiary, Trigen Laboratories, Inc., renamed Jubilant Pharmaceuticals, Inc., a generic pharmaceutical company in USA having a US FDA approved formulations manufacturing facility -Enters Clinsys Clinical Research Ltd. business by setting up wholly owned subsidiary Jubilant Clinsys Ltd. 2006 -Selected as one of the top 25 companies for Institute of Company Secretaries of India National Award for Excellence in Corporate Governance -Finalist in Golden Peacock Award for Excellence in Corporate Governance -Company has splits its Face value of Shares from Rs 5 to Re 1 2007 -Jubilant Organosys Ltd has acquired 100% equity stake in Hollister-Stier Laboratories LLC, USA, engaged in high growth Injectable contract manufacturing and well established and stable Allergy Immunotherapy businesses. -Acquires Hollister Stier Laboratories in USA, a contract manufacturer of Sterile injectable vials and allergenic extracts. 2008 -Acquires DRAXIS Specialty Pharmaceuticals, Inc. Canada, a contract manufacturer of sterile & non-sterile products and radiopharmaceuticals -Acquires Speciality Molecules Pvt. Ltd. Engaged in the manufacturing of Fine Chemicals used by Life Science Industry including pharma, agro & cosmetic industry. -Jubilant Organosys and Lilly form Drug development joint venture - Uttar Pradesh-based pharma major Jubilant Organosys Ltd (JOL) has secured new contracts worth $92 million (Rs.3.7 billion). The contracts have been signed under Customs Research and Manufacturing Services (CRAMS). Besides marketing its products in the regulated markets of the US, Europe and Japan, the company has managed to make forays into China, said a statement of JOL. 2009 -Jubilant enters into multiple Drug discovery partnerships with leading pharma and biotech -companies such as AstraZeneca, Orion, Endo pharmaceuticals & BioLeap and also extends its collaboration with Lilly for five years. -Jubilant enters into drug development collaborations with academia, University of Alabama at Birmingham and Southern Research Institute (USA) and Duke University (Singapore). -Jubilant Kalpataru - 120 bed super specialty hospital at Barasat, Kolkata, India inaugurated by Hon'ble Minister of Finance Shri Pranab Mukherjee 2010 -ET - IMEA 2009 Platinum Award by Frost & Sullivan, in the Pharmaceutical category for the API facility at Nanjangud -Best CFO (FMCG, Health and Retail Sector) to Mr. R. Sankaraiah by Institute of Chartered Accountants of India in January, 2010 - Jubilant Organosys Ltd has appointed Mr. Shardul S. Shroff as Additional Director of the Company with effect from March 15, 2010. - Jubilant Organosys Ltd has signed a USD 51 million CRAMS contract with a leading Life Sciences Company 2010 -The Company has changed from "Jubilant Organosys Ltd" to "JUBILANT LIFE SCIENCES LTD" -Mr. Shardul S. Shroff has been appointed as Additional Director of the Company. 2011 -Jubilant Life Sciences Ltd has announced another successful delivery of an early stage milestone in the Pain therapeutic area. -Jubilant Org - Jubilant sets up global scale capacities for Symtet - developed through 2012 -JubilantLife - announced today that they have achieved an early stage milestone in one of their collaborative programs with Chadds Ford. -"Jubilant HollisterStier Announces Multi-Million Dollar Award for the manufacture of Sterile Parenteral Products". -"Jubilant SEZ at Bharuch, inaugurated by Shri Narendra Modi, Hon'ble Chief Minister of Gujarat". 2013 - "Jubilant Life Sciences receives prestigious NDTV Profit Business Leadership Award 2012 for Corporate Social Responsibility." - Jubilant Life Sciences receives ANDA approval for Quetiapine Fumarate Tablet -Jubilant Life Sciences declared winner of Supply Chain Excellence Awards' at 7th Express, Logistics & Supply Chain Leadership Awards 2013 2014 - Jubilant Life Scienc - Results of Tender Offer for acquisition of minority shares of Cadista Holdings Inc. - Board recommended a Dividend of Rs.3 per equity shares of Rs.1 -Jubilant Life Sciences wins Excellence Awards at `India Pharma Awards' 2014 -Jubilant Life Sciences conferred with Golden Peacock Business Excellence Award-2014 2015 -Gold Award in Ankleshwar Chapter Convention on Quality Concepts 2015 (ACCQC) -Two Honors at the 10th Annual CIO100 Awards by CIO Magazine - CIO100 Innovation Architect Special Awards 2015 and Versatile 100honorees -Golden Peacock National Quality Award for Quality -Dataquest Business Technology Awards for Best IT Implementation in Analytics, Mobility, Cloud, ERP/CSM/CRM -ASSOCHAM's `Responsible Organization Excellence' Award 2014-15 -50 Most Talented Sustainability Leaders Award -15th Annual Greentech Environment Award 2014 - Gold Category winner under Chemicals and Pharmaceutical sector" - Gajraula plant, India -I.C.O.N.I.C IDC Insights Award, under `Health and Life Sciences vertical 2016 - Jubilant Life Sciences Limited won the Sustainability Award for Best Green Process in Chemical sector of FICCI Chemicals & Petrochemicals Awards, 2016.

Registered Office

Bhartiagram, Gajraula

5924-252351,252356,252358,      5924-252352,

investors@jubl.com

http://www.jubl.com

Registrar Details

Alankit Assignment Ltd.